Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | TFPI | P10646 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299155 | 0.94 | SIRT2 (0.44) | SIRT2SIRT5OPRL1 | |
| SCHEMBL16299143 | 0.92 | F2 (0.53) | VIPR1TFPIOPRL1F2VIPR2 | |
| SCHEMBL16299136 | 0.92 | F2 (0.53) | VIPR1TFPIOPRL1F2VIPR2 | |
| SCHEMBL10168771 | 0.92 | F2 (0.53) | VIPR1TFPIOPRL1F2VIPR2 | |
| SCHEMBL10168550 | 0.92 | RXFP1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16299151 | 0.92 | ENPEP (0.42) | RXFP1VIPR1SIRT2SIRT5 | |
| SCHEMBL16299113 | 0.92 | ENPEP (0.43) | SIRT2SIRT5 | |
| SCHEMBL16299137 | 0.92 | TFPI (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10169060 | 0.91 | RXFP1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16299117 | 0.91 | TFPI (0.54) | RXFP1VIPR1TFPIOPRL1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | GRIN2D 2822/4885GRIN3B 1470/4885GRIN1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.